Tasly Pharmaceutical Group Co (SHSE:600535) Other Current Liabilities: ¥53 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600535 Tasly Pharmaceutical Group Co Ltd SHSE:600535
78 GF Score
Price ¥15.73
GF Value ¥15.12
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Tasly Pharmaceutical Group Co Other Current Liabilities?

Tasly Pharmaceutical Group Co SHSE:600535 -1.19% 78 Other Current Liabilities is ¥53 Mil as of Mar. 2026. GuruFocus rates SHSE:600535 with a GF Score™ of 78/100 and a GF Value™ of ¥15.12 (Fairly Valued). The stock has 3 warning signs investors should review.

Tasly Pharmaceutical Group Co's other current liabilities for the quarter that ended in Mar. 2026 was ¥53 Mil.

Tasly Pharmaceutical Group Co's quarterly other current liabilities declined from Sep. 2025 (¥118 Mil) to Dec. 2025 (¥53 Mil) and declined from Dec. 2025 (¥53 Mil) to Mar. 2026 (¥53 Mil).

Tasly Pharmaceutical Group Co's annual other current liabilities declined from Dec. 2023 (¥169 Mil) to Dec. 2024 (¥136 Mil) and declined from Dec. 2024 (¥136 Mil) to Dec. 2025 (¥53 Mil).

Tasly Pharmaceutical Group Co Other Current Liabilities Related Terms

Tasly Pharmaceutical Group Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Tasly Pharmaceutical Group Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tasly Pharmaceutical Group Co Other Current Liabilities Chart

Tasly Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 175.81 161.54 168.68 135.99 52.92

Tasly Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.29 133.58 117.90 52.92 52.65
SHSE:600535
78GF Score
Tasly Pharmaceutical Group Co Ltd SHSE:600535
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tasly Pharmaceutical Group Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ¥53 Mil mean?
Tasly Pharmaceutical Group Co (SHSE:600535) has a Other Current Liabilities of ¥53 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Tasly Pharmaceutical Group Co.
Is Tasly Pharmaceutical Group Co's Other Current Liabilities too high?
Tasly Pharmaceutical Group Co's current Other Current Liabilities is ¥53 Mil. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's Other Current Liabilities compare to ZTS?
Tasly Pharmaceutical Group Co's Other Current Liabilities of ¥53 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Tasly Pharmaceutical Group Co. Tasly Pharmaceutical Group Co's current Other Current Liabilities is ¥53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.12, compared to a current price of ¥15.73 — trading 4% above its estimated fair value. The current Other Current Liabilities is ¥53 Mil. Tasly Pharmaceutical Group Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current Other Current Liabilities is ¥53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?

Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥15.73 is trading 4% above its estimated GF Value™ of ¥15.12. GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:600535:

  • Other Current Liabilities: ¥53 Mil
  • GF Value™: ¥15.12 vs. price of ¥15.73 (4% above fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tasly Pharmaceutical Group Co Business Description

Address 2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
78GF Score

Get the complete analysis for SHSE:600535

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.73
Price
¥15.12
GF Value